Press release Biocartis Group NV: US Multicenter Study Shows Idylla™ Allows Rapid and Accurate Mutation Testing Results Across Different Laboratory Settings

NEXT STORY
DBV Technologies Provides Operational and Business Update
PREV STORY
Translate Bio Announces Pricing of Public Offering of Common Stock
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Apricus Biosciences, Inc. Announces Merger Agreement with Seelos Therapeutics, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders

Transaction to result in Nasdaq-listed company focused on developing novel products to treat central ...

author_avatar
NASDAQ Market News

Dova Pharmaceuticals Announces New Drug Application Submission to FDA for Avatrombopag, a Second Generation Thrombopoietin Receptor Agonist

DURHAM, N.C., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a specialty ...

author_avatar
NASDAQ Market News

ExCellThera announces results of clinical trial using ECT-001 for blood cancers

MONTREAL, Dec. 04, 2018 (GLOBE NEWSWIRE) -- ExCellThera Inc., a biotechnology company delivering molecules ...

author_avatar
NASDAQ Market News